Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-World Registry Study to Evaluate Clinical Protection Outcomes Following Post-Exposure Prophylaxis With Zamerovimab and Mazorelvimab Injection in Combination With Rabies Vaccine in Pediatric With Category III Rabies Exposure

NCT07327307 is registered in ClinicalTrials.gov with Synermore Biologics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT07327307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07327307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-World Registry Study to Evaluate Clinical Protection Outcomes Following Post-Exposure Prophylaxis With Zamerovimab and Mazorelvimab Injection in Combination With Rabies Vaccine in Pediatric With Category III Rabies Exposure
Lead sponsor
Synermore Biologics (Suzhou) Co., Ltd.
Phase
Observational
Overall status
Recruiting
Start date
August 2, 2025
Completion date
December 31, 2026
Enrollment
232 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

rabies post-exposure prophylaxis